Company intelligence / Profile preview

Bett

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Better Therapeutics was a prescription digital therapeutics company focused on developing software-based solutions to treat cardiometabolic diseases. The company's lead product, AspyreRx, was the first FDA-authorized prescription digital therapeutic for the treatment of type 2 diabetes, utilizing cognitive behavioral therapy to drive behavioral changes. Despite achieving commercial-stage status, the company faced significant financial challenges and announced a cessation of operations and liquidation in early 2024. Its platform aimed to address the root causes of chronic diseases by modifying behaviors related to diet and lifestyle.

Therapeutic areas: CardiovascularEndocrinologyGastroenterology
Modalities: Digital therapeuticsSoftware as a Medical Device (SaMD)
Industry: Digital Health Medical Devices

Partnerships

Gelesis

Beyond the preview

Go deeper on Bett.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bett.

Explore the full profile